DLQ01
Androgenetic Alopecia (Male & Female Pattern Hair Loss)
Phase 2Active
Key Facts
Indication
Androgenetic Alopecia (Male & Female Pattern Hair Loss)
Phase
Phase 2
Status
Active
Company
About Dermaliq Therapeutics
Dermaliq Therapeutics is a private, clinical-stage biotech company leveraging its proprietary hyliQ® drug delivery platform to create superior topical dermatology treatments. Its primary focus is on androgenetic alopecia, where its lead asset DLQ01 has shown promising Phase 2a results in men, demonstrating a >500% relative hair count improvement versus vehicle. The company aims to address the significant unmet need in hair loss, particularly for women who lack effective topical options, by enabling targeted follicular delivery of potent drug classes like prostaglandin analogs.
View full company profile